Evidence map›Paper›PMID 40647542›Full record

ArticleCancers2025

Oncogenic Activity and Sorafenib Sensitivity of

Carol Lee, Weixue Mu, Xi July Chen, Mandy Sze Man Chan, Zhishan Chen, Sai Fung Yeung, Helen Hoi Yin Chan, Sin Ting Chow, Ben Chi Bun Ko, David Wai Chan and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Carol LeeSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.ORCID 0009-0001-9722-1103
Weixue MuSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.ORCID 0000-0002-2675-261X
Xi July ChenSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.ORCID 0009-0004-1270-757X
Mandy Sze Man ChanSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.
Zhishan ChenSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.
Sai Fung YeungSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.ORCID 0000-0002-6518-0562
Helen Hoi Yin ChanSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.
Sin Ting ChowSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.ORCID 0009-0009-1295-5705
Ben Chi Bun KoDepartment of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong.
David Wai ChanSchool of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
William C ChoDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong.ORCID 0000-0003-4174-4586
Vivian Wai Yan LuiSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.
Stephen Kwok Wing TsuiSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.ORCID 0000-0003-0686-4259

Funding

Research Impact Fund (#R4015-19) from the Research Grants Council of the Hong Kong Special Administrative Region #R4015-19
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ARAF p.S214C mutationlung canceroncogenicitysorafenib sensitivity

Identifiers

PMID40647542
PMCPMC12248905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.